Literature DB >> 11593388

Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.

R R Hoover1, M J Gerlach, E Y Koh, G Q Daley.   

Abstract

The Akt, Ras and STAT5 signaling pathways have each been linked to transformation of hematopoietic cells by BCR/ABL. However the relative contributions of these signaling pathways to BCR/ABL mediated cytokine-independent survival, proliferation and resistance to DNA damage-induced apoptosis have not been systematically defined. Here we report that activation of either Akt, Ras or STAT5 confers cytokine-independent survival to IL-3 dependent BaF3 cells. Ras or STAT5, but not Akt, also drives cytokine-independent proliferation and imparts sustained resistance to DNA damage-induced apoptosis. We also show that dominant negative (DN) inhibition of STAT5, but not Ras or Akt, significantly reduces resistance to DNA damage-induced apoptosis in BCR/ABL transformed BaF3 cells. Whereas inhibition of STAT5 or Ras alone does not compromise cytokine-independent proliferation of BaF3-BCR/ABL cells, simultaneous blockade of both STAT5 and Ras reduces proliferation and maximally sensitizes BaF3-BCR/ABL cells to DNA damage induced by gamma-irradiation, suggesting a cooperative role for these two signaling pathways in BCR/ABL transformation. The anti-apoptotic properties of BCR/ABL can be partly explained by an increase in the expression of Pim-1 and Bcl-XL, as ectopic expression of these STAT5 target genes imparts both cytokine-independent survival and partial gamma-radiation resistance. These data illustrate both cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed cells, with STAT5 playing a dominant role in resistance to DNA damage-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11593388     DOI: 10.1038/sj.onc.1204549

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  Enhanced hematopoietic differentiation of embryonic stem cells conditionally expressing Stat5.

Authors:  Michael Kyba; Rita C R Perlingeiro; Russell R Hoover; Chi-Wei Lu; Jonathan Pierce; George Q Daley
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

2.  Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Filippo Prencipe; Carlota Lopez-Cara; Riccardo Rondanin; Daniele Simoni; Ernest Hamel; Stefania Grimaudo; Rosaria Maria Pipitone; Maria Meli; Manlio Tolomeo
Journal:  Eur J Med Chem       Date:  2015-11-27       Impact factor: 6.514

3.  MiRNA-1469 promotes lung cancer cells apoptosis through targeting STAT5a.

Authors:  Chengshan Xu; Ling Zhang; Hengheng Li; Zhihua Liu; Lianning Duan; Chengrong Lu
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

4.  miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Authors:  Anna M Eiring; Jason G Harb; Paolo Neviani; Christopher Garton; Joshua J Oaks; Riccardo Spizzo; Shujun Liu; Sebastian Schwind; Ramasamy Santhanam; Christopher J Hickey; Heiko Becker; Jason C Chandler; Raul Andino; Jorge Cortes; Peter Hokland; Claudia S Huettner; Ravi Bhatia; Denis C Roy; Stephen A Liebhaber; Michael A Caligiuri; Guido Marcucci; Ramiro Garzon; Carlo M Croce; George A Calin; Danilo Perrotti
Journal:  Cell       Date:  2010-03-05       Impact factor: 41.582

5.  ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.

Authors:  Valentina Nardi; Olaia Naveiras; Mohammad Azam; George Q Daley
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

6.  Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.

Authors:  L Schafranek; E Nievergall; J A Powell; D K Hiwase; T Leclercq; T P Hughes; D L White
Journal:  Leukemia       Date:  2014-05-12       Impact factor: 11.528

Review 7.  Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.

Authors:  E K Thomas; J A Cancelas; Y Zheng; D A Williams
Journal:  Leukemia       Date:  2008-03-20       Impact factor: 11.528

8.  An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.

Authors:  T Pene-Dumitrescu; L F Peterson; N J Donato; T E Smithgall
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

9.  STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells.

Authors:  Zsuzsanna S Nagy; Matthew J LeBaron; Jeremy A Ross; Abhisek Mitra; Hallgeir Rui; Robert A Kirken
Journal:  Mol Cancer       Date:  2009-08-26       Impact factor: 27.401

10.  Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Authors:  Peter Valent
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.